Should GLP-1 patches complete clinical development and receive regulatory approval in future, they would undergo health technology assessment by NICE to determine cost-effectiveness and appropriate positioning within NHS treatment pathways
Yes, some patients experience temporary fatigue during the initial treatment phase due to gastrointestinal side effects (nausea, vomiting, diarrhoea) or reduced caloric intake
The cardiovascular phenomenon of endothelial dysfunction involves a series of structural and functional abnormalities, including abnormal secretory capacity and properties of the endothelium and impaired vascular tone, as well as an impaired endothelial barrier function
These drugs mimic the glucagon-like peptide-1 hormone, which regulates appetite and insulin secretion
Cefalo CMA, Cinti F, Moffa S, Impronta F, Sorice GP, Mezza T, Pontecorvi A, Giaccari A
Jan 20, 2026 9 min read IN THIS ARTICLE KEY TAKEAWAYS GLP-1 medications can reduce appetite and temporarily lower energy
